| Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. | |
| | |
MedLine Citation:
|
PMID: 17805217 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Generalized anxiety disorder (GAD) is a chronic illness with psychic and somatic symptoms that do not respond uniformly in the first weeks of treatment. METHODS: A post-hoc analysis of pooled data from five placebo-controlled, double-blind, randomized studies in non-depressed GAD patients treated with venlafaxine extended release (ER) or placebo was performed to determine the temporal response of psychic and somatic symptoms to treatment over 8 weeks. Two of the studies included extension phases of up to 6 months, the results of which were also analyzed here. RESULTS: The earliest symptoms to respond included both psychic symptoms (anxious mood, tension, behavior at interview) and somatic muscular, cardiovascular, and respiratory symptoms. The last symptoms to respond included the psychic symptoms of insomnia and fear and the somatic sensory, gastrointestinal and autonomic symptoms, perhaps in part because of drug-related side effects. Continuing treatment beyond 8 weeks in venlafaxine ER responders for up to 6 months of total treatment results not only in additional improvement in early-responding symptoms, but also in the improvement of late-responding symptoms, perhaps due in part to the development of tolerance to antidepressant side effects. CONCLUSION: Serious consideration should be given to maintaining partial responders to venlafaxine ER treatment on the same treatment for > or = 3-6 months. |
| | |
Authors:
|
Stephen M Stahl; Saeeduddin Ahmed; Vincent Haudiquet |
Related Documents
:
|
12393307 - Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depre... 17466657 - A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. 8415897 - Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. 18539007 - A double-blind dose-finding pilot study of docosahexaenoic acid (dha) for major depress... 11376917 - Depressive symptoms modulate the subjective and physiological response to cocaine in hu... 16507047 - Definition of at-risk patients: dynamic variables. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: CNS spectrums Volume: 12 ISSN: 1092-8529 ISO Abbreviation: CNS Spectr Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-09-06 Completed Date: 2007-10-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9702877 Medline TA: CNS Spectr Country: United States |
Other Details:
|
Languages: eng Pagination: 703-11 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA. smstahl@neiglobal.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anxiety Disorders / diagnosis*, drug therapy*, psychology Cyclohexanols / therapeutic use* Dose-Response Relationship, Drug Double-Blind Method Female Humans Male Serotonin Uptake Inhibitors / therapeutic use* Somatoform Disorders / diagnosis*, drug therapy*, psychology |
| Chemical | |
Reg. No./Substance:
|
0/Cyclohexanols; 0/Serotonin Uptake Inhibitors; 93413-69-5/venlafaxine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The neuropsychiatry of adrenomyeloneuropathy.
Next Document: Akathisia: problem of history or concern of today.